Clinical Trial

Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchiectasis

Study acronym: NOVEL
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to learn about new sensors that measure changes in the body that happen during a chest infection, such as breathing rate and heart rate. This study will be with adults who have either cystic fibrosis or bronchiectasis who start treatment with intravenous antibiotics (usually for around 2 weeks). The main question it aims to answer is the change in sensor measure (such as heart rate) between the start and end of treatment for a chest infection. No follow up visits are required for this study.
Trial Details
NCT Number NCT07289100
Lead Sponsor Papworth Hospital NHS Foundation Trust
Collaborators: LifeArc, University of Cambridge, Department of Health, United Kingdom, National Institute for Health Research, United Kingdom
Conditions Cystic Fibrosis (CF), Bronchiectasis Adult
Enrollment 50 participants
Start Date 2025-09-30
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-17